GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Overview

Journal Diabetes

Specialty Endocrinology

Date 2009 Jan 20

PMID 19151200

Citations 238

Authors

Mohammad Hossein Noyan-Ashraf

M Abdul Momen

Kiwon Ban

Al-Muktafi Sadi

Yu-Qing Zhou

Ali M Riazi

Laurie L Baggio

R Mark Henkelman

Mansoor Husain

Daniel J Drucker

Affiliations

Soon will be listed here.

Abstract

Objective: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear.

Research Design And Methods: We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide.

Results: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 +/- 2% versus 29 +/- 3%, P = 0.02) and improved cardiac output (12.4 +/- 0.6 versus 9.7 +/- 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3beta, PPARbeta-delta, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R-dependent manner in vitro.

Conclusions: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo.

Citing Articles

Ferroptosis: mechanism and role in diabetes-related cardiovascular diseases.

Wang Z, Wu C, Yin D, Dou K Cardiovasc Diabetol. 2025; 24(1):60.

PMID: 39920799 PMC: 11806630. DOI: 10.1186/s12933-025-02614-x.

Glucagon-Like Peptide-1 Links Ingestion, Homeostasis, and the Heart.

Krieger J, Daniels D, Lee S, Mastitskaya S, Langhans W Compr Physiol. 2025; 15(1):e7.

PMID: 39887844 PMC: 11790259. DOI: 10.1002/cph4.7.

The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.

Lu C, Xu C, Yang J Medicina (Kaunas). 2025; 61(1).

PMID: 39858999 PMC: 11767243. DOI: 10.3390/medicina61010017.

Contractile Effects of Semaglutide in the Human Atrium.

Neumann J, Hadova K, Klimas J, Hofmann B, Gergs U Pharmaceutics. 2024; 16(9).

PMID: 39339176 PMC: 11435389. DOI: 10.3390/pharmaceutics16091139.

Glucose-Lowering Drugs with Proven Cardiovascular Benefit Following Acute Coronary Syndrome in Patients with Type 2 Diabetes: Treatment Gaps and Outcomes.

Naoum I, Saliba W, Barnett-Griness O, Aker A, Zafrir B J Clin Med. 2024; 13(18).

PMID: 39337027 PMC: 11432281. DOI: 10.3390/jcm13185541.

References

Li R, Mickle D, Weisel R, Zhang J, Mohabeer M . In vivo survival and function of transplanted rat cardiomyocytes. Circ Res. 1996; 78(2):283-8. DOI: 10.1161/01.res.78.2.283. View

Barragan J, Eng J, Rodriguez R, Blazquez E . Neural contribution to the effect of glucagon-like peptide-1-(7-36) amide on arterial blood pressure in rats. Am J Physiol. 1999; 277(5):E784-91. DOI: 10.1152/ajpendo.1999.277.5.E784. View

Shiraishi I, Melendez J, Ahn Y, Skavdahl M, Murphy E, Welch S . Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res. 2004; 94(7):884-91. DOI: 10.1161/01.RES.0000124394.01180.BE. View

Kavianipour M, Ehlers M, Malmberg K, Ronquist G, Ryden L, Wikstrom G . Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides. 2003; 24(4):569-78. DOI: 10.1016/s0196-9781(03)00108-6. View

Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen Y . Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006; 317(3):1106-13. DOI: 10.1124/jpet.106.100982. View

Drucker D, Nauck M . The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696-705. DOI: 10.1016/S0140-6736(06)69705-5. View

Aulinger B, DAlessio D . Glucagon-like peptide 1: continued advances, new targets and expanding promise as a model therapeutic. Curr Opin Endocrinol Diabetes Obes. 2007; 14(1):68-73. DOI: 10.1097/MED.0b013e328013e79e. View

Burkart E, Sambandam N, Han X, Gross R, Courtois M, Gierasch C . Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest. 2007; 117(12):3930-9. PMC: 2082147. DOI: 10.1172/JCI32578. View

Degn K, Juhl C, Sturis J, Jakobsen G, Brock B, Chandramouli V . One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004; 53(5):1187-94. DOI: 10.2337/diabetes.53.5.1187. View

10.

Cook S, Sugden P, Clerk A . Regulation of bcl-2 family proteins during development and in response to oxidative stress in cardiac myocytes: association with changes in mitochondrial membrane potential. Circ Res. 1999; 85(10):940-9. DOI: 10.1161/01.res.85.10.940. View

11.

Liu X, Pachori A, Ward C, Davis J, Gnecchi M, Kong D . Heme oxygenase-1 (HO-1) inhibits postmyocardial infarct remodeling and restores ventricular function. FASEB J. 2006; 20(2):207-16. DOI: 10.1096/fj.05-4435com. View

12.

Yang Z, Berr S, Gilson W, Toufektsian M, French B . Simultaneous evaluation of infarct size and cardiac function in intact mice by contrast-enhanced cardiac magnetic resonance imaging reveals contractile dysfunction in noninfarcted regions early after myocardial infarction. Circulation. 2004; 109(9):1161-7. DOI: 10.1161/01.CIR.0000118495.88442.32. View

13.

Sokos G, Nikolaidis L, Mankad S, Elahi D, Shannon R . Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006; 12(9):694-9. DOI: 10.1016/j.cardfail.2006.08.211. View

14.

Heineke J, Molkentin J . Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol. 2006; 7(8):589-600. DOI: 10.1038/nrm1983. View

15.

Nikolaidis L, Elahi D, Shen Y, Shannon R . Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2005; 289(6):H2401-8. DOI: 10.1152/ajpheart.00347.2005. View

16.

Vila Petroff M, Egan J, Wang X, Sollott S . Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res. 2001; 89(5):445-52. DOI: 10.1161/hh1701.095716. View

17.

Ohta K, Nakajima T, Cheah A, Zaidi S, Kaviani N, Dawood F . Elafin-overexpressing mice have improved cardiac function after myocardial infarction. Am J Physiol Heart Circ Physiol. 2003; 287(1):H286-92. DOI: 10.1152/ajpheart.00479.2002. View

18.

Nikolaidis L, Doverspike A, Hentosz T, Zourelias L, Shen Y, Elahi D . Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther. 2004; 312(1):303-8. DOI: 10.1124/jpet.104.073890. View

19.

Bose A, Mocanu M, Carr R, Yellon D . Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther. 2007; 21(4):253-6. DOI: 10.1007/s10557-007-6030-6. View

20.

Larsen P, Fledelius C, Knudsen L, Tang-Christensen M . Systemic administration of the long-acting GLP-1 derivative NN2211 induces lasting and reversible weight loss in both normal and obese rats. Diabetes. 2001; 50(11):2530-9. DOI: 10.2337/diabetes.50.11.2530. View